Health ❯ Healthcare

Obesity

Treatment Options Weight Management Weight Loss Weight Loss Treatments Treatment Weight Loss Drugs Health Risks Medications Obesity Management Obesity Treatment

Heart Risks Rebound After GLP-1 Breaks, New Data Show Continuous Use Is Safest

A three-year Veterans Affairs analysis ties treatment pauses to higher cardiovascular events.

FDA Approves First Therapy for Acquired Hypothalamic Obesity, Expanding Rhythm’s Imcivree

FDA Clears 7.2‑mg Wegovy as India Enters Generic Semaglutide Era

India Braces for 50+ Semaglutide Generics as Patent Expires Friday

Biomea Fusion Reports Positive 52-Week Phase II Results for Icovamenib in Diabetes

Most Weight Lost on GLP-1 Drugs Returns After Stopping, New Analysis Finds

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

Lilly Launches FDA-Cleared Monthly Zepbound KwikPen on LillyDirect at $299 Starter Price

Private GLP-1 Weight-Loss Use in UK Skews to Middle-Class Women, Analysis Shows

Ramadan Fasting: Doctors Urge Stable GLP-1 Use, Warn Against Starting or Raising Doses

Lilly Combo of Zepbound and Taltz Tops Taltz Alone in Late-Stage Psoriasis Trials

NHS Starts Targeted Mounjaro Prescribing as Norfolk–Waveney ICB Estimates Over 11,000 Eligible

Boots Pilots First High‑Street Prescribing Service for Wegovy and Mounjaro

GLP-1 Era Hits the Mainstream With Super Bowl Ads as Costs Rise and Care Shifts to Maintenance

GLP-1 Weight-Loss Boom Triggers Safety Warnings and New Oversight

Novo Nordisk Forecasts Up to 13% 2026 Sales and Profit Decline as U.S. Price Cuts Bite

Anvisa Expands Wegovy and Ozempic Uses to Cardiovascular and Kidney Protection

UK Regulator Flags Rare Pancreatitis, Including Deaths, Tied to Wegovy and Mounjaro

CagriSema Beats Semaglutide on HbA1c and Weight at 68 Weeks in Type 2 Diabetes Trial